Associations of the BNT162b2 COVID-19 vaccine effectiveness with patient age and comorbidities at daily resolution
Yelin, I.; Katz, R.; Herzel, E.; Berman-Zilberstein, T.; Ben-Tov, A.; Kuint, J.; Gazit, S.; Patalon, T.; Chodick, G.; Kishony, R.
Show abstract
Vaccinations are considered the major tool to curb the current SARS-CoV-2 pandemic. A randomized placebo-controlled trial of the BNT162b2 vaccine has demonstrated a 95% efficacy in preventing COVID-19 disease. These results are now corroborated with statistical analyses of real-world vaccination rollouts, but resolving vaccine effectiveness across demographic groups is challenging. Here, applying a multivariable logistic regression analysis approach to a large patient-level dataset, including SARS-CoV-2 tests, vaccine inoculations and personalized demographics, we model vaccine effectiveness at daily resolution and its interaction with sex, age and comorbidities. Vaccine effectiveness gradually increased post day 12 of inoculation, then plateaued, around 35 days, reaching 91.2% [CI 88.8%-93.1%] for all infections and 99.3% [CI 95.3%-99.9%] for symptomatic infections. Effectiveness was uniform for men and women yet declined mildly but significantly with age and for patients with specific chronic comorbidities, most notably type 2 diabetes. Quantifying real-world vaccine effectiveness, including both biological and behavioral effects, our analysis provides initial measurement of vaccine effectiveness across demographic groups.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Adherence and sustainability of interventions informing optimal control against COVID-19 pandemic 94%
- The potential impact of Omicron and future variants of concern on SARS-CoV-2 transmission dynamics and public health burden: a modelling study 94%
- Wearable Sensor and Digital Twin Technology for the Development of a Personalized Digital Biomarker of Vaccine-Induced Inflammation 94%
Similar papers in this journal
- Effect of booster vaccination against Delta and Omicron variants in Iceland 95%
- Racial and ethnic differences in COVID-19 vaccine hesitancy and uptake 94%
- Waning of SARS-CoV-2 antibodies targeting the Spike protein in individuals post second dose of ChAdOx1 and BNT162b2 COVID-19 vaccines and risk of breakthrough infections: analysis of the Virus Watch community cohort 94%
Similar papers in this journal
Similar papers in this journal
- Comparison of COVID-19 vaccine prioritization strategies in the United States 95%
- COVID-19 vaccines that reduce symptoms but do not block infection need higher coverage and faster rollout to achieve population impact 94%
- Multi-strain modeling of influenza vaccine effectiveness in older adults and its dependence on antigenic distance 94%
Similar papers in this journal
- Protection of previous SARS-CoV-2 infection is similar to that of BNT162b2 vaccine protection: A three-month nationwide experience from Israel 96%
- Using LASSO regression to estimate the population-level impact of pneumococcal conjugate vaccines 94%
- Waning of two-dose BNT162b2 and mRNA-1273 vaccine effectiveness against symptomatic SARS-CoV-2 infection is robust to depletion-of-susceptibles bias 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.